Baxter Healthcare manufactured a C-1 inhibitor protein, extracted
from human blood and heat-sterilized, for HAE in Europe. However,
this treatment, which was administered intravenously, is no longer
available. Aventis now distributes a plasma-based product in Europe
and is making it available on a limited basis in the United States.
For information about obtaining the Aventis product, patients and
physicians should contact the Immune Deficiency Foundation in Maryland:
Immune Deficiency Foundation
40 West Chesapeake Avenue
Suite 308
Towson, MD 21230
Telephone: (410) 321-6647
Toll Free: (800) 296-4433
e-mail: jb@primaryimmune.org
Web site: http://www.primaryimmune.org
Dyax Corporation is developing a recombinant form of the HAE C-1 inhibitor
called DX-88 for the treatment of patients who have acute, episodic attacks
of HAE. Clinical trials of this biotechnology product are underway. This
product does not contain human plasma. Dyax refers to the study as EDEMA 1
(Evaluation of DX-88’s Effect on Mitigating Angioedema). Treatment centers
are being established (December 2002) in the United States and worldwide.
Patients 10 years of age or older who suffer from acute attacks of HAE are
eligible for inclusion in the trial. Participants will be administered one
dose by intravenous infusion, and will be followed for a period of 28 days.
In the United States, patients and parents or guardians of patients may call
an automated call center at 866-814-4915 to register for the EDEMA 1 trial.
For additional information, contact:
Clinical Operations
Dyax Corp.
300 Technology Square
Cambridge, MA 02139
Telephone: (617) 225-2500
Read about events on Capitol Hill, funding for rare-disease research, and other topics of interest from NORD's office in Washington, DC.
